The mRNA Vaccine and Biomanufacturing Centre at Biovectra's Charlottetown campus has begun development.
The 36,000-square-foot facility will be able to produce 160 million doses of mRNA vaccines per year, with 70 million doses packed and ready for commercial distribution.
Other advances included the projected completion of a single-use clinical-size microbiological suite in Windsor, Nova Scotia, and the opening of a new research and development facility in Halifax, Nova Scotia, as part of the programme.
Both of these initiatives have been added to BIOVECTRA's Windsor facility. This is to help with the creation and production of plasmid DNA, which is used to make mRNA treatments and vaccines.
BIOVECTRA will also begin developing and producing nucleic acids, as well as expanding its capability for enhancing microbial proteins and other biotherapeutics through microbial fermentation.
In 2023, the facility is planned to open for operations.